Clinigen launches European managed access program for Tesaro's Zejula

Clinigen Group plc (LSE:CLIN) launched a managed access program in Europe for PARP inhibitor niraparib (MK-4827) from Tesaro Inc. (NASDAQ:TSRO) to treat recurrent ovarian cancer.

In March, FDA approved the drug as Zejula for maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in patients in complete or partial response to platinum-based chemotherapy (see BioCentury, March 30). An MAA for the product is under EMA review...